Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press16810.17650/2220-3478-2016-6-2-8-17ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯFactors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancerФакторы, ассоциированные с эффективностью поддерживающей химиотерапии при метастатическом раке толстой кишкиFedyaninM. Yu.ФедянинМ. Ю.Russian Federationfedianinmu@mail.ruTryakinA. A.ТрякинА. А.Russian FederationPolyanskayaE. M.ПолянскаяЕ. М.Russian FederationPokataevI. A.ПокатаевИ. А.Russian FederationSheinaO. V.СехинаО. В.Russian FederationKozlovN. A.КозловН. А.Russian FederationStrogonovaA. M.СтрогоноваА. М.Russian FederationGordeevS. S.ГордеевС. С.Russian FederationKuz’michevD. V.КузьмичевД. В.Russian FederationAlievV. A.АлиевВ. А.Russian FederationSagaydakI. V.СагайдакИ. В.Russian FederationRasulovS. A.РасуловА. О.Russian FederationTyulandinS. A.ТюляндинС. А.Russian FederationN. N. Blokhin Russian Cancer Research Center of the Ministry of Health of RussiaФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» Минздрава России23 Kashirskoe shosse, Moscow, 115478, RussiaРоссия, 115478, Москва, Каширское шоссе, 2305082016628170508201605082016Copyright ©; 2016, Fedyanin M.Y., Tryakin A.A., Polyanskaya E.M., Pokataev I.A., Sheina O.V., Kozlov N.A., Strogonova A.M., Gordeev S.S., Kuz’michev D.V., Aliev V.A., Sagaydak I.V., Rasulov S.A., Tyulandin S.A.Copyright ©; 2016, Федянин М.Ю., Трякин А.А., Полянская Е.М., Покатаев И.А., Сехина О.В., Козлов Н.А., Строгонова А.М., Гордеев С.С., Кузьмичев Д.В., Алиев В.А., Сагайдак И.В., Расулов А.О., Тюляндин С.А.2016Fedyanin M.Y., Tryakin A.A., Polyanskaya E.M., Pokataev I.A., Sheina O.V., Kozlov N.A., Strogonova A.M., Gordeev S.S., Kuz’michev D.V., Aliev V.A., Sagaydak I.V., Rasulov S.A., Tyulandin S.A.Федянин М.Ю., Трякин А.А., Полянская Е.М., Покатаев И.А., Сехина О.В., Козлов Н.А., Строгонова А.М., Гордеев С.С., Кузьмичев Д.В., Алиев В.А., Сагайдак И.В., Расулов А.О., Тюляндин С.А.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/168colon cancerunresectable metastasesmaintenance chemotherapyfirst-line therapysecond-line therapyprogression-free survivalfluoropyrimidinesрак толстой кишкинеоперабельные метастазыподдерживающая химиотерапиятерапия 1-й линиитерапия 2-й линиивыживаемость без прогрессированияфторпиримидины[1. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207–14.Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207–14.][2. Chibaudel B., Tournigand C., Perez- Staub N. et al. Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC). J Clin Oncol 2009;27 (suppl; abstr 4073):15s.Chibaudel B., Tournigand C., Perez- Staub N. et al. Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC). J Clin Oncol 2009;27 (suppl; abstr 4073):15s.][3. Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006;24:394– 400.Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006;24:394– 400.][4. Chibaudel B., Bonnetain F., Tournigand C., et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal. The cancer: a GERCOR study. Oncologist 2011;16(9):1228–38.Chibaudel B., Bonnetain F., Tournigand C., et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal. The cancer: a GERCOR study. Oncologist 2011;16(9):1228–38.][5. Perez-Staub N., Chibaude B., Figer A. et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. J Clin Oncol 2008;26 (Suppl):4037.Perez-Staub N., Chibaude B., Figer A. et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. J Clin Oncol 2008;26 (Suppl):4037.][6. Li Y. H., Luo H. Y., Wang F. H. et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2010;136(4):503–10.Li Y. H., Luo H. Y., Wang F. H. et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2010;136(4):503–10.][7. Petrioli R., Paolelli L., Marsili S. et al. FOLFOX4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006;70(5):345– 50.Petrioli R., Paolelli L., Marsili S. et al. FOLFOX4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006;70(5):345– 50.][8. Scalamogna R., Brugnatelli S., Tinelli C. et al. UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. Oncology 2007;72(5–6):267–73.Scalamogna R., Brugnatelli S., Tinelli C. et al. UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. Oncology 2007;72(5–6):267–73.][9. Nakayama G., Kodera Y., Yokoyama H. et al. Modified FOLFOX6 with oxaliplatin stop-and- go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. Int J Clin Oncol 2011;16:506–11.Nakayama G., Kodera Y., Yokoyama H. et al. Modified FOLFOX6 with oxaliplatin stop-and- go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. Int J Clin Oncol 2011;16:506–11.][10. Luo H. Y., Li Y. H., Wang W. et al. Singleagent capecitabineas maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016;27(6):1074–81.Luo H. Y., Li Y. H., Wang W. et al. Singleagent capecitabineas maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016;27(6):1074–81.][11. Diaz-Rubio E., Gomez-Espana A., Massuti B. et al. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study. OncologistDiaz-Rubio E., Gomez-Espana A., Massuti B. et al. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study. Oncologist][2012;17(1):15–25.;17(1):15–25.][12. Koopman M., Simkens L. H. J., Tije A. J. T. et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2013;31(suppl):abstr 3502.Koopman M., Simkens L. H. J., Tije A. J. T. et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2013;31(suppl):abstr 3502.][13. Koeberle D., Betticher D. C., von Moos R. et al. Bevacizumab continuation versus no continuation after first-line chemobevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). J Clin Oncol 2013;31(suppl):abstr 3503.Koeberle D., Betticher D. C., von Moos R. et al. Bevacizumab continuation versus no continuation after first-line chemobevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). J Clin Oncol 2013;31(suppl):abstr 3503.][14. Moscetti L., Cortesi E., Gamucci T. et al. Maintenance treatment with bevacizumab after chemotherapy (CT) plus B in metastatic colorectal cancer: An Italian multicenter retrospective analysis. J Clin Oncol 2011;29 (suppl):abstr e14043.Moscetti L., Cortesi E., Gamucci T. et al. Maintenance treatment with bevacizumab after chemotherapy (CT) plus B in metastatic colorectal cancer: An Italian multicenter retrospective analysis. J Clin Oncol 2011;29 (suppl):abstr e14043.][15. Tournigand C., Chibaudel B., Samson B. et al. Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. J Clin Oncol 2013;31(suppl):abstr 3515.Tournigand C., Chibaudel B., Samson B. et al. Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. J Clin Oncol 2013;31(suppl):abstr 3515.][16. Pfeiffer P., Sorbye H., Qvortrup C. et al. Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2012;30:(suppl):abstr 3538.Pfeiffer P., Sorbye H., Qvortrup C. et al. Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2012;30:(suppl):abstr 3538.][17. Tveit K. M., Guren T., Glimelius B. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC–VII study. J Clin Oncol 2012;30(15):1755–62.Tveit K. M., Guren T., Glimelius B. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC–VII study. J Clin Oncol 2012;30(15):1755–62.][18. Wasan H., Adams R. A., Wilson R. H. et al. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the twoarm phase II randomized MRC COIN-b trial. J Clin Oncol 2012;30(suppl 4):abstr 536.Wasan H., Adams R. A., Wilson R. H. et al. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the twoarm phase II randomized MRC COIN-b trial. J Clin Oncol 2012;30(suppl 4):abstr 536.][19. Koopman M., Simkens L., May A. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3):abstr LBA388.Koopman M., Simkens L., May A. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3):abstr LBA388.]